Kindstar Globalgene Technology, Inc.

Equities

9960

KYG5262E1044

Healthcare Facilities & Services

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
1.6 ^HKD	+2.56%		+4.58%	-4.76%

Mar. 27	Kindstar Globalgene Technology, Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 27 September 2024	CI
Mar. 27	Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shenzhen Fanyin Medical Co., Ltd. announced that it has received funding from Rivercity Investment, Spark Venture Capital, Kindstar Global Technology, Inc.

November 24, 2021

Shenzhen Fanyin Medical Co., Ltd. announced that it has received funding led by new investor Ruijiang Investment on November 25, 2021. The transaction also included participation from new investor Kindstar Global (Beijing) Technology, Inc., Spark Venture Capital and Rivercity Investment.

Latest news about Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc. Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 27 September 2024	Mar. 27	CI
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Kindstar Globalgene Arm to Setup 300 Million Yuan PE Fund	Nov. 13	MT
Kindstar Globalgene Technology, Inc.(SEHK:9960) dropped from S&P Global BMI Index	23-09-18	CI
Kindstar Globalgene Logs 31% Drop in H1 Income	23-08-18	MT
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Kindstar Globalgene Units form Partnership with Two Parties to Boost Investment Income	23-06-19	MT
Kindstar Globalgene Technology, Inc. commences an Equity Buyback Plan for 99,051,118 shares, representing 10% of its issued share capital, under the authorization approved on June 1, 2023.	23-06-01	CI
Kindstar Globalgene Technology, Inc.'s Equity Buyback announced on June 23, 2022, has expired.	23-05-31	CI
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI
Kindstar Trustee Buys 13 Million Shares in Nine Months Through September	22-10-03	MT
Kindstar Globalgene Technology, Inc.(SEHK:9960) added to S&P Global BMI Index	22-09-19	CI
Kindstar Globalgene Swings to H1 Profit	22-08-15	MT
Kindstar Globalgene Technology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-15	CI
Kindstar Globalgene Technology, Inc. Announces Executive Changes	22-08-15	CI
Kindstar Globalgene Expects Up to $10 Million Profit in H1	22-08-02	MT
Kindstar Globalgene Technology, Inc. Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022	22-08-01	CI
Kindstar Globalgene Technology, Inc. Announces Change of Address of Principal Place of Business in Hong Kong	22-07-28	CI
Kindstar Globalgene Expects Swing to Profit in H1; Shares Jump 9%	22-07-20	MT
Kindstar Globalgene Technology, Inc. Provides Earnings Guidance for the Half Year Ended 30 June 2022	22-07-20	CI
Kindstar Globalgene Technology's RSU Trustee Buys 7.9 Million Shares	22-07-06	MT
Kindstar Globalgene Technology CEO Increases Shareholding in Company	22-07-05	MT
Kindstar Globalgene Technology, Inc. commences an Equity Buyback Plan for 99,399,528 shares, representing 10% of its issued share capital, under the authorization approved on June 1, 2022.	22-06-23	CI
Kindstar Global Technology, Inc. Reappoints Ernst & Young as the Auditor	22-06-01	CI
Kindstar Globalgene Technology, Inc.'s Equity Buyback announced on November 10, 2021, has expired.	22-05-31	CI

Chart Kindstar Globalgene Technology, Inc.

Duration

Period

Chart Kindstar Globalgene Technology, Inc.

More charts

Company Profile

Kindstar Globalgene Technology Inc is a China-based investment holding company principally engaged in the provision of clinical testing services. The Company operates nine segments. Hematology Testing segment includes testing services related to blood diseases. Genetic Diseases and Rare Diseases segment includes testing services from the rare disease. Infectious Diseases segment includes testing services from the infection department. Oncology segment includes testing related to oncology diseases. Neurology segment includes testing services related to neurological diseases undertaken by the Group. Maternity-related Diseases segment includes testing services related to maternity. COVID-19 Related Testing segment includes testing services related to COVID-19. Routine Testing segment conducts routine tests for the doctorsâ daily diagnoses. The Others segment includes testing services for research and development (R&D) projects and others and miscellaneous services.

Sector

Healthcare Facilities & Services

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Kindstar Globalgene Technology, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.6

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
KINDSTAR GLOBALGENE TECHNOLOGY, INC.	-4.76%	190M
SONIC HEALTHCARE LIMITED	-17.89%	8.36B
RADNET, INC.	+39.66%	3.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.73B
SYNLAB AG	-8.06%	2.47B
DR. LAL PATHLABS LIMITED	-7.35%	2.32B
NEOGENOMICS, INC.	-11.84%	1.77B
FLEURY S.A.	-19.18%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.22B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.09B

Medical & Diagnostic Laboratories